MBBS, MD, MRCP,@ D.Phil, FRACP, Senior Staff Specialist, Gold Coast University Hospital, Qld; Adjunct Associate Professor, Faculty of Health Sciences and Medicine, Bond University, Qld.
MBBS, FRACP, FCSANZ, Interventional Cardiologist, Gold Coast University Hospital, Qld; Associate Professor, School of Medicine, Griffith University, Qld.
Aust J Gen Pract. 2021 Jul;50(7):441-444. doi: 10.31128/AJGP-12-20-5764.
COVID-19 has been at the forefront of public and scientific attention since the initial report in December 2019. The kidney is one of the target organs of the causative SARS-CoV-2 virus.
The aim of this article is to discuss the current understanding of COVID-19 renal disease from a primary care perspective, with the caveat that our knowledge of the pathogenesis, clinical course and outcome of the disease is still rapidly evolving.
The kidney is one of the target organs of the causative SARS-CoV-2 virus, affecting the endothelium, podocytes and renal tubular epithelial cells. Clinical presentation ranges from isolated proteinuria, haematuria to severe acute kidney injury (AKI) requiring renal replacement therapy. Renal dysfunction associated with COVID-19 has a worse prognosis whether it be in the form of AKI or worsening of pre-existing chronic kidney disease, or in patients undergoing renal replacement therapy.
自 2019 年 12 月首次报告以来，COVID-19 一直是公众和科学界关注的焦点。肾脏是 SARS-CoV-2 病毒的靶器官之一。
本文旨在从初级保健的角度讨论 COVID-19 肾脏疾病的现有认识，但需要注意的是，我们对疾病的发病机制、临床过程和结果的认识仍在迅速发展。
肾脏是 SARS-CoV-2 病毒的靶器官之一，影响血管内皮细胞、足细胞和肾小管上皮细胞。临床表现范围从孤立性蛋白尿、血尿到需要肾脏替代治疗的严重急性肾损伤（AKI）。与 COVID-19 相关的肾功能障碍，无论是 AKI 还是原有慢性肾脏病的恶化，或在接受肾脏替代治疗的患者中，其预后均较差。
